san diego, californiaand sydney, australia (friday ... · united states australia ... – data to...

_________________________________________________________________________________________

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

Presentation at J.P. Morgan Healthcare Conference

San Diego, California and Sydney, Australia (Friday, 16 January 2015, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) confirms as previously announced that its Chairman and CEO, Bob Stockman, presented at the 33rd Annual J.P. Morgan Healthcare Conference at 11:30 a.m. US PST on Thursday, January 15, 2015. The conference was held January 12th through 15th at The Westin St. Francis Hotel in San Francisco, California.

The presentation materials delivered at the conference are attached hereto. A copy of these presentation materials are also being filed with the U.S. Securities and Exchange Commission and posted under the Investor Relations section of REVA’s website at www.revamedical.com.

About REVA REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds are currently in clinical studies and have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial intended commercial product, the FantomTM scaffold, has been designed to offer distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products. United States Australia Australia Investor & Media Enquiries: Investor Enquiries: Media Enquiries: REVA Medical, Inc. Inteq Limited Buchan Consulting Cheryl Liberatore Kim Jacobs Rebecca Wilson Director, Investor Relations +61 2 9229 2700 +61 3 9866 4722 +1 858-966-3045 Annabel Murphy +61 2 9237 2800 F

or p

erso

nal u

se o

nly

2015 REVA Medical, Inc. 0

January 15, 2015

J.P. Morgan 2015 Healthcare Conference

For

per

sona

l use

onl

y


Important Notice Information is a Synopsis Only This presentation only contains a synopsis of information on the Company and, accordingly, no reliance may be placed for any purpose whatsoever on the sufficiency or completeness of such information. Information presented in this presentation is subject to change without notice and REVA does not have any responsibility or obligation to inform you of any matter arising or coming to their notice after the date of this presentation, which may affect any matter in the presentation.

Currency References Financial amounts in this presentation are expressed in US Dollars, except where specifically noted.

Forward-Looking Statements This presentation contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, and estimates regarding our capital requirements and financial performance, including profitability. You should not place undue reliance on these forward-looking statements. Although management believes these forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in the forward-looking statements, which risks and uncertainties are described in the “Risk Factors” section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on March 17, 2014, and as updated in our periodic reports since then.. Any forward-looking statements in this presentation speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Disclaimer This presentation and any supplemental materials have been prepared by the Company based on available information. The information contained in this presentation is an overview and does not contain all information necessary to make an investment decision. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of the Company, or any of its members, directors, officers, employees, or agents or advisers, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of the Company or any of its directors, officers, employees, or agents.

For

per

sona

l use

onl

y


Corporate Summary • Pre-revenue, clinical-stage company

• Focused on development of bioresorbable scaffolds for the treatment of coronary artery disease

• Single facility located in San Diego, CA

– Development labs – Manufacturing facilities – Corporate offices

• ASX listed (RVA.AX); SEC registered

• ISO 13485:2012 certified

• 47 employees

• Experienced and invested executive management and board of directors

• Strong patent portfolio

For

per

sona

l use

onl

y


Key 2014 Accomplishments

• Developed Fantom™, a novel bioresorbable scaffold to offer the desired advancements for a second generation product

• Completed Q4’14 $25 million financing to support REVA’s timeframe to CE Mark approval of Fantom

– Goldman Sachs and Senrigan

– Other existing key investors include Domain Partners, Elliott Associates, Saints Capital, Brookside Capital, Cerberus and Medtronic

• Initiated first human implants of Fantom Q4’14

– Data to be presented at industry conferences beginning May 2015 (EuroPCR)

For

per

sona

l use

onl

y


CORE PRODUCT VALUES

REVA Core

Product Values

REstore VAsomotion Innovation

Patient Safety Procedural Ease

For

per

sona

l use

onl

y


Product Development Approach

Minimize risk through the use of proven technologies

• Known device: standard deformable design

• Proven drug: Sirolimus

• Standard rapid exchange delivery system

Create valuable product advancements through innovative technology

• Well-studied REVA polycarbonate polymer

– Enables the only fully visible bioresorbable scaffold

– Allows for ease-of-use features including single-step inflation and scaffold expansion

– Polymer family has 10-year proven safety history

For

per

sona

l use

onl

y


Bioresorbable Scaffold Market

For

per

sona

l use

onl

y


Evolution of Treatments of Coronary Artery Disease

Proprietary images licensed from the American Heart Association

Open Heart Surgery CABG

1960s

Bioresorbable Drug-Eluting Scaffolds

2013 and beyond

Balloon Angioplasty

1970s

Bare Stents

1990s 2002

Drug-Eluting Stents

For

per

sona

l use

onl

y


The Appeal of a Bioresorbable Scaffold (“BRS”)

• Clinically preferable – Preserves maximum flexibility for future

treatment options (bypass grafting, distal stenting)

– May delay disease progression and reduce the rate of future clinical events

– May enable future preventative therapy

• Intuitively preferred by patients

– Allows artery to return to its natural state to restore freedom of movement (vasomotion)

– Suited for patients needing multiple treatments, especially young patients

Internet-enabled patients may help drive market

For

per

sona

l use

onl

y


Bioresorbable Scaffolds Today’s Snapshot

• Clinical data continues to demonstrate safety and additional potential BRS benefits – Comparable MACE (7.3% vs. 9.1%)* and low stent thrombosis (0.6%)*

– Restoration of natural vasomotion

– Signal for reduced angina (recurrent chest pain) in BRS patients

• BRS being used in complex cases (CTOs, bifurcations, left main)

• Physicians seeking improvements in 2nd generation devices – Thinner, more deliverable, easier to use; no compromise on strength

* Absorb II Study of 500+ patients, Absorb vs. Xience DES, one-year

data published by Abbott Vascular September 14, 2014

For

per

sona

l use

onl

y


“Bioresorbable scaffolds have the potential to transform the way coronary artery disease is treated. With further advancements bioresorbable scaffold usage may be as

high as 80% within the next ten years.“

Dean Kereiakes, M.D., FACC, FSCAI

Principal Investigator, Absorb III and IV US Clinical Trials Medical Director, The Christ Hospital Heart & Vascular Center

and the Lindner Research Center in Cincinnati, OH Professor of clinical medicine at Ohio State University F

or p

erso

nal u

se o

nly


Coronary Stent Market

Today’s Market Projected 2025 Market

*JP Morgan Interventional Cardiology Market Model August 2014 Includes: US, Europe, Japan and other Asian Countries

2014E revenues $4.2b worldwide*

80% BRS Usage

BRS has the potential to dominate the future coronary stent market. Which players will capitalize on the shifting dynamics?

For

per

sona

l use

onl

y


Fantom™ Sirolimus-Eluting Bioresorbable Scaffold

For

per

sona

l use

onl

y


Disappears to restore

natural vasomotion

Fantom Delivering the Next Advancement in Bioresorbable Scaffolds

FANTOM

Visible

Deliverable Thin Struts

Drug Eluting

Easy to Use

Strong

For

per

sona

l use

onl

y


Fantom is Completely Visible Under X-Ray

• Fantom’s complete visibility under standard fluoroscopy (x-ray) increases confidence during the procedure

– Precise scaffold placement

– Accurate lesion coverage

– Confirmation of apposition to vessel wall

– Reduces need for IVUS catheter use (saving $)

– No permanent metal markers left behind

Fantom is the only completely visible bioresorbable scaffold

Absorb Fantom Xience Fantom

For

per

sona

l use

onl

y


Fantom is Designed with Thinner Struts

Fantom achieves low strut thickness without sacrificing scaffold strength

Strut Thickness Comparison

* Metal Drug-Eluting Stent

Absorb(ABT)

Cypher*(JNJ)

TAXUS*(BSC)

FANTOM(REVA)

Integrity*(MDT)

Xience*(ABT)

For

per

sona

l use

onl

y


Fantom is Designed with Thinner Struts

Reduced strut thickness minimizes material in the vessel

Strut Thickness Comparison

Fantom Absorb

For

per

sona

l use

onl

y


Fantom Enables Standard Implant Procedure

• Single-step inflation directly to intended diameter

– No need for intermediate inflation steps

• Post-dilation without compromise

– Substantial expansion safety margin

– Able to adjust for vessel taper

3.0mm Nominal Device

Polymer enables expansion to > 4.8mm without fracture

Ease of use and substantial safety margin

For

per

sona

l use

onl

y


Fantom Offers Optimal Degradation Profile

• Greater than 80% degradation within one year

– Restoration of natural vasomotion

– Eliminates undesirable shear stress induced by a permanent implant

For

per

sona

l use

onl

y


Fantom Preclinical Results Confirm Performance

Deliverability Vessel Patency Visibility

For

per

sona

l use

onl

y


Commercializing Fantom

For

per

sona

l use

onl

y


Clinical Program • First human implants initiated December 2014 • Clinical program will include up to 30 sites in 9 countries

For

per

sona

l use

onl

y


Commercialization

• CE Mark approval anticipated mid-2016

• Actively planning early commercialization efforts

– First launch to target EU

– Follow-on launch planning underway

– Direct sales force or distribution partnership with Boston Scientific

For

per

sona

l use

onl

y


Protecting the Fantom Scaffold

REVA Filings and Exclusively Licensed Patents Core Technology

Protected through 2030 - 2034

2014 2018 2022 2026 2030 2034

For

per

sona

l use

onl

y


REVA Summary

• Financial resources secured to meet clinical and commercialization objectives

• In clinical trials with competitive and differentiated bioresorbable scaffold product

• Planning of early commercialization efforts underway

• Market potential for bioresorbable scaffolds is substantial and will be fueled by advancements in technology

Stay tuned for Fantom clinical data results at EuroPCR 2015

For

per

sona

l use

onl

y


Thank You

For

per

sona

l use

onl

y

san diego, californiaand sydney, australia (friday ... · united states australia ... – data to...

Documents